Skip Navigation


QJM Advance Access originally published online on February 12, 2008
QJM 2008 101(4):327-329; doi:10.1093/qjmed/hcn009
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/4/327    most recent
hcn009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Librez, A.S.
Right arrow Articles by Sibert, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Librez, A.S.
Right arrow Articles by Sibert, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Ureteral nephrogenic adenoma in antiphospholipid antibody syndrome

A.S. Librez, I. Marie, N. Cailleux and H. Levesque

Department of Internal Medicine

A. François

Department of Pathologic
Histology and Cytology

L. Sibert

Department of Urology,
Rouen University Hospital,
76031 Rouen Cedex,
France
email: isabelle.marie@chu-rouen.fr

The first 10% of the full text of this article appears below.

Sir,

Primary antiphospholipid antibody syndrome (PAPS) is characterized by recurrent venous and arterial thrombosis, or both, or repeated fetal loss, associated with the presence of anticardiolipin (acL) or anti-β2 glycoprotein 1 (anti-β2 GP1) antibody or lupus anticoagulant (LAC) on two samples at least 8 weeks apart, in the absence of other connective-tissue disorders.1 Systemic manifestations are well recognized complications of PAPS. Renal involvement is not an uncommon complication of the disease, occurring in as many as 2.7–30% of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?